VNDA
Vanda Pharmaceuticals Inc.
Biotechnology
Market Cap$378M
5Y Perf.-45.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
VNDA vs SUPN vs PCRX vs PTCT
Revenue, margins, valuation, and 5-year total return — side by side.
SUPN
Supernus Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$3.01B
5Y Perf.+116.7%
PCRX
Pacira BioSciences, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$930M
5Y Perf.-46.2%
PTCT
PTC Therapeutics, Inc.
Biotechnology
Market Cap$5.35B
5Y Perf.+27.2%
VNDA vs SUPN vs PCRX vs PTCT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VNDA | SUPN | PCRX | PTCT |
|---|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $378M | $3.01B | $930M | $5.35B |
| Revenue (TTM) | $218M | $777M | $735M | $827M |
| Net Income (TTM) | $-240M | $-29M | $9M | $-187M |
| Gross Margin | 71.1% | 89.4% | 60.2% | 49.7% |
| Operating Margin | -73.6% | -5.5% | 3.4% | -8.3% |
| Forward P/E | — | 24.1x | 8.6x | 8.3x |
| Total Debt | $13M | $41M | $454M | $492M |
| Cash & Equiv. | $85M | $128M | $159M | $985M |
VNDA vs SUPN vs PCRX vs PTCT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VNDA
SUPN
PCRX
PTCT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Vanda Pharmaceutica… (VNDA) | 100 | 54.5 | -45.5% |
| Supernus Pharmaceut… (SUPN) | 100 | 216.7 | +116.7% |
| Pacira BioSciences,… (PCRX) | 100 | 53.8 | -46.2% |
| PTC Therapeutics, I… (PTCT) | 100 | 127.2 | +27.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VNDA vs SUPN vs PCRX vs PTCT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PCRX leads in 3 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. PTC Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. SUPN also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
VNDA
Vanda Pharmaceuticals Inc.
The Secondary Option
VNDA lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
SUPN
Supernus Pharmaceuticals, Inc.
The Momentum Pick
SUPN is the clearest fit if your priority is momentum.
- +69.0% vs PCRX's -6.1%
Best for: momentum
PCRX
Pacira BioSciences, Inc.
The Income Pick
PCRX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.47
- Lower volatility, beta 0.47, Low D/E 65.6%, current ratio 4.54x
- Beta 0.47, current ratio 4.54x
- 1.3% margin vs VNDA's -110.0%
Best for: income & stability and sleep-well-at-night
PTCT
PTC Therapeutics, Inc.
The Growth Play
PTCT is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 114.5%, EPS growth 264.5%, 3Y rev CAGR 35.3%
- 7.3% 10Y total return vs SUPN's 228.4%
- 114.5% revenue growth vs PCRX's 3.6%
- Lower P/E (8.3x vs 24.1x)
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PTCT | 114.5% revenue growth vs PCRX's 3.6% |
| Value | PTCT | Lower P/E (8.3x vs 24.1x) |
| Quality / Margins | PCRX | 1.3% margin vs VNDA's -110.0% |
| Stability / Safety | PCRX | Beta 0.47 vs PTCT's 1.13 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | SUPN | +69.0% vs PCRX's -6.1% |
| Efficiency (ROA) | PCRX | 0.7% ROA vs VNDA's -44.6%, ROIC 2.3% vs -32.2% |
VNDA vs SUPN vs PCRX vs PTCT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
FY 2025
FY 2025
VNDA vs SUPN vs PCRX vs PTCT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPCRXLAGGINGPTCT
Who Leads Where
PCRX leads in 2 of 6 categories
SUPN leads 1 • VNDA leads 0 • PTCT leads 0 • 2 tied
Explore the data ↓PTCTPTC Therapeutics, Inc.
0leads
VNDAVanda Pharmaceuticals…
0leads
SUPNSupernus Pharmaceutic…
1leads
PCRXPacira BioSciences, I…
2leads
6 Total Categories
CATEGORYLEADERvs SUPNvs VNDAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
PCRX3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PCRX5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
SUPN5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — SUPN and PCRX each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PTCT is the larger business by revenue, generating $827M annually — 3.8x VNDA's $218M. PCRX is the more profitable business, keeping 1.3% of every revenue dollar as net income compared to VNDA's -110.0%. On growth, SUPN holds the edge at +38.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | VNDAVanda Pharmaceuti… | SUPNSupernus Pharmace… | PCRXPacira BioScience… | PTCTPTC Therapeutics,… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $218M | $777M | $735M | $827M |
| EBITDAEarnings before interest/tax | -$150M | $29M | $95M | -$37M |
| Net IncomeAfter-tax profit | -$240M | -$29M | $9M | -$187M |
| Free Cash FlowCash after capex | -$127M | $82M | $133M | -$229M |
| Gross MarginGross profit ÷ Revenue | +71.1% | +89.4% | +60.2% | +49.7% |
| Operating MarginEBIT ÷ Revenue | -73.6% | -5.5% | +3.4% | -8.3% |
| Net MarginNet income ÷ Revenue | -110.0% | -3.7% | +1.3% | -22.6% |
| FCF MarginFCF ÷ Revenue | -58.5% | +10.6% | +18.1% | -27.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.4% | +38.6% | +5.0% | -76.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -64.0% | +81.0% | -30.0% | -100.3% |
Evenly matched — SUPN and PCRX each lead in 3 of 6 comparable metrics.
Valuation Metrics
PCRX leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 8.3x trailing earnings, PTCT trades at a 94% valuation discount to PCRX's 147.8x P/E. On an enterprise value basis, PTCT's 5.4x EV/EBITDA is more attractive than SUPN's 53.4x.
| Metric | VNDAVanda Pharmaceuti… | SUPNSupernus Pharmace… | PCRXPacira BioScience… | PTCTPTC Therapeutics,… |
|---|---|---|---|---|
| Market CapShares × price | $378M | $3.0B | $930M | $5.3B |
| Enterprise ValueMkt cap + debt − cash | $305M | $2.9B | $1.2B | $4.9B |
| Trailing P/EPrice ÷ TTM EPS | -1.71x | -76.88x | 147.75x | 8.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 24.12x | 8.61x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 53.44x | 9.86x | 5.42x |
| Price / SalesMarket cap ÷ Revenue | 1.75x | 4.19x | 1.28x | 3.09x |
| Price / BookPrice ÷ Book value/share | 1.15x | 2.78x | 1.54x | — |
| Price / FCFMarket cap ÷ FCF | — | 65.45x | 6.80x | 7.61x |
PCRX leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
PCRX leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
PCRX delivers a 1.3% return on equity — every $100 of shareholder capital generates $1 in annual profit, vs $-61 for VNDA. VNDA carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to PCRX's 0.66x. On the Piotroski fundamental quality scale (0–9), PCRX scores 9/9 vs VNDA's 2/9, reflecting strong financial health.
| Metric | VNDAVanda Pharmaceuti… | SUPNSupernus Pharmace… | PCRXPacira BioScience… | PTCTPTC Therapeutics,… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -61.4% | -2.7% | +1.3% | — |
| ROA (TTM)Return on assets | -44.6% | -2.0% | +0.7% | -6.8% |
| ROICReturn on invested capital | -32.2% | -2.8% | +2.3% | — |
| ROCEReturn on capital employed | -33.6% | -3.4% | +2.8% | +55.9% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 | 9 | 7 |
| Debt / EquityFinancial leverage | 0.04x | 0.04x | 0.66x | — |
| Net DebtTotal debt minus cash | -$72M | -$87M | $296M | -$492M |
| Cash & Equiv.Liquid assets | $85M | $128M | $159M | $985M |
| Total DebtShort + long-term debt | $13M | $41M | $454M | $492M |
| Interest CoverageEBIT ÷ Interest expense | — | — | 2.37x | -1.67x |
PCRX leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
SUPN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SUPN five years ago would be worth $17,801 today (with dividends reinvested), compared to $3,578 for VNDA. Over the past 12 months, SUPN leads with a +69.0% total return vs PCRX's -6.1%. The 3-year compound annual growth rate (CAGR) favors SUPN at 12.4% vs PCRX's -17.6% — a key indicator of consistent wealth creation.
| Metric | VNDAVanda Pharmaceuti… | SUPNSupernus Pharmace… | PCRXPacira BioScience… | PTCTPTC Therapeutics,… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -22.5% | +5.7% | -3.4% | -16.0% |
| 1-Year ReturnPast 12 months | +45.9% | +69.0% | -6.1% | +58.2% |
| 3-Year ReturnCumulative with dividends | -7.8% | +42.1% | -44.1% | +16.1% |
| 5-Year ReturnCumulative with dividends | -64.2% | +78.0% | -62.6% | +60.3% |
| 10-Year ReturnCumulative with dividends | -26.8% | +228.4% | -51.2% | +733.2% |
| CAGR (3Y)Annualised 3-year return | -2.7% | +12.4% | -17.6% | +5.1% |
SUPN leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SUPN and PCRX each lead in 1 of 2 comparable metrics.
Risk & Volatility
PCRX is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than PTCT's 1.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SUPN currently trades 87.6% from its 52-week high vs VNDA's 64.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VNDAVanda Pharmaceuti… | SUPNSupernus Pharmace… | PCRXPacira BioScience… | PTCTPTC Therapeutics,… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.04x | 0.78x | 0.47x | 1.13x |
| 52-Week HighHighest price in past year | $9.94 | $59.68 | $27.64 | $87.50 |
| 52-Week LowLowest price in past year | $3.81 | $29.16 | $18.80 | $37.94 |
| % of 52W HighCurrent price vs 52-week peak | +64.3% | +87.6% | +85.5% | +73.7% |
| RSI (14)Momentum oscillator 0–100 | 54.9 | 57.9 | 45.9 | 45.3 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 604K | 695K | 1.0M |
Evenly matched — SUPN and PCRX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: VNDA as "Buy", SUPN as "Buy", PCRX as "Hold", PTCT as "Buy". Consensus price targets imply 121.8% upside for VNDA (target: $14) vs 14.8% for SUPN (target: $60).
| Metric | VNDAVanda Pharmaceuti… | SUPNSupernus Pharmace… | PCRXPacira BioScience… | PTCTPTC Therapeutics,… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $14.17 | $60.00 | $29.50 | $89.67 |
| # AnalystsCovering analysts | 19 | 14 | 36 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +16.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PCRX leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). SUPN leads in 1 (Total Returns). 2 tied.
Best OverallPacira BioSciences, Inc. (PCRX)Leads 2 of 6 categories
Loading custom metrics...
VNDA vs SUPN vs PCRX vs PTCT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is VNDA or SUPN or PCRX or PTCT a better buy right now?
For growth investors, PTC Therapeutics, Inc.
(PTCT) is the stronger pick with 114. 5% revenue growth year-over-year, versus 3. 6% for Pacira BioSciences, Inc. (PCRX). PTC Therapeutics, Inc. (PTCT) offers the better valuation at 8. 3x trailing P/E, making it the more compelling value choice. Analysts rate Vanda Pharmaceuticals Inc. (VNDA) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VNDA or SUPN or PCRX or PTCT?
On trailing P/E, PTC Therapeutics, Inc.
(PTCT) is the cheapest at 8. 3x versus Pacira BioSciences, Inc. at 147. 8x. On forward P/E, Pacira BioSciences, Inc. is actually cheaper at 8. 6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — VNDA or SUPN or PCRX or PTCT?
Over the past 5 years, Supernus Pharmaceuticals, Inc.
(SUPN) delivered a total return of +78. 0%, compared to -64. 2% for Vanda Pharmaceuticals Inc. (VNDA). Over 10 years, the gap is even starker: PTCT returned +733. 2% versus PCRX's -51. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VNDA or SUPN or PCRX or PTCT?
By beta (market sensitivity over 5 years), Pacira BioSciences, Inc.
(PCRX) is the lower-risk stock at 0. 47β versus PTC Therapeutics, Inc. 's 1. 13β — meaning PTCT is approximately 141% more volatile than PCRX relative to the S&P 500. On balance sheet safety, Vanda Pharmaceuticals Inc. (VNDA) carries a lower debt/equity ratio of 4% versus 66% for Pacira BioSciences, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — VNDA or SUPN or PCRX or PTCT?
By revenue growth (latest reported year), PTC Therapeutics, Inc.
(PTCT) is pulling ahead at 114. 5% versus 3. 6% for Pacira BioSciences, Inc. (PCRX). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to -1068. 8% for Vanda Pharmaceuticals Inc.. Over a 3-year CAGR, PTCT leads at 35. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VNDA or SUPN or PCRX or PTCT?
PTC Therapeutics, Inc.
(PTCT) is the more profitable company, earning 39. 4% net margin versus -102. 0% for Vanda Pharmaceuticals Inc. — meaning it keeps 39. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus -70. 0% for VNDA. At the gross margin level — before operating expenses — PTCT leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VNDA or SUPN or PCRX or PTCT more undervalued right now?
On forward earnings alone, Pacira BioSciences, Inc.
(PCRX) trades at 8. 6x forward P/E versus 24. 1x for Supernus Pharmaceuticals, Inc. — 15. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VNDA: 121. 8% to $14. 17.
08Which pays a better dividend — VNDA or SUPN or PCRX or PTCT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is VNDA or SUPN or PCRX or PTCT better for a retirement portfolio?
For long-horizon retirement investors, Pacira BioSciences, Inc.
(PCRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). Both have compounded well over 10 years (PCRX: -51. 2%, VNDA: -26. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VNDA and SUPN and PCRX and PTCT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: VNDA is a small-cap quality compounder stock; SUPN is a small-cap quality compounder stock; PCRX is a small-cap quality compounder stock; PTCT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(VNDA: 3.4% · SUPN: 38.6%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.